Biogen traded at $291.92 this Thursday January 26th, decreasing $0.42 or 0.14 percent since the previous trading session. Looking back, over the last four weeks, Biogen lost 6.24 percent. Over the last 12 months, its price rose by 33.33 percent. Looking ahead, we forecast Biogen to be priced at 276.34 by the end of this quarter and at 249.87 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
291.92
Daily Change
-0.14%
Yearly
33.33%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 147.40 -0.56 -0.38% 8.41%
Acadia Pharmaceuticals 18.66 -0.03 -0.16% -13.33%
Acorda Therapeutics 0.95 -0.02 -2.42% -44.36%
ALKERMES 28.50 0.16 0.56% 16.04%
Amgen 254.88 -1.66 -0.65% 13.79%
Bayer 56.32 0.28 0.50% 6.61%
Biogen 291.92 -0.42 -0.14% 33.33%
Bluebird Bio 6.23 -0.10 -1.58% -14.66%
BioMarin Pharmaceutical 116.98 0.95 0.82% 40.85%
Bristol-Myers Squibb 72.99 -0.18 -0.25% 12.45%
Esperion Therapeutics 6.65 -0.04 -0.60% 82.19%
Gilead Sciences 83.62 -0.45 -0.54% 21.43%
Intercept Pharmaceuticals 18.37 -0.18 -0.97% 27.22%
Incyte Corp 86.01 1.04 1.22% 20.14%
Intra Cellular Therapies 48.77 0.53 1.10% 7.28%
Eli Lilly 348.01 -1.72 -0.49% 41.99%
Merck & Co 106.87 -1.72 -1.58% 32.10%
Moderna Inc 193.24 0.17 0.09% 30.02%
Marinus Pharmaceuticals 5.94 -0.02 -0.34% -37.01%
Neurocrine Biosciences 108.38 -0.42 -0.39% 49.59%
Novartis 82.30 -0.38 -0.46% 3.69%
Puma Biotechnology 4.42 -0.17 -3.70% 96.44%
Pfizer 44.19 -0.88 -1.95% -17.20%
PTC Therapeutics 45.99 -0.38 -0.82% 19.39%
Ultragenyx Pharmaceutical 44.14 0.74 1.71% -31.39%
Regeneron Pharmaceuticals 742.30 1.12 0.15% 18.78%
Sanofi 89.50 -0.22 -0.25% -5.05%
Seattle Genetics 139.69 1.68 1.22% 13.65%
Sangamo BioSciences 3.45 -0.03 -0.86% -37.50%
Sanofi 48.81 -0.08 -0.16% -7.66%
Sarepta Therapeutics 124.47 1.31 1.06% 86.11%
Teva Pharmaceutical Industries Ltd 3,459.00 54.00 1.59% 27.17%
United Therapeutics 264.23 -1.69 -0.64% 35.38%
Vertex Pharmaceuticals 321.02 5.74 1.82% 32.10%

Indexes Price Day Year
US500 4049 44.21 1.10% -8.63%
USND 11512 199.06 1.76% -13.78%
USNDX 11986 236.79 2.00% -17.08%

Biogen
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.